BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250904T150000
DTEND;TZID=America/Los_Angeles:20250904T160000
DTSTAMP:20250801T002154Z
CREATED:20250617T061031Z
LAST-MODIFIED:20250801T002154Z
UID:42167-1756998000-1757001600@solvecfs.org
SUMMARY:Targeting Autophagy: A Clinical Trial of Low-Dose Rapamycin for ME/CFS\, Long COVID\, and IACCIs
DESCRIPTION:Simmaron Research is the second recipient of Solve’s ME/CFS Catalyst Award in support of its study\,” “Low Dose Rapamycin in ME/CFS\, Long-COVID\, and Other Infection-Associated Chronic Conditions.” \nRead a preprint from Phase 1 of the trial here. \nThe study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid\, repurposing rapamycin to reduce fatigue\, orthostatic intolerance\, post-exertional malaise\, and sleep issues for a subset of people with ME/CFS. \nIn this webinar led by Solve M.E. President Emily Taylor\, panelists Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron) and Dr. Avik Roy (Chief Scientific Officer at Simmaron)\, and Dr. Stephanie Grach (Assistant Professor of Medicine and Consultant in General Internal Medicine at Mayo Clinic-Rochester) will discuss the study\, which hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).  Attendees will learn how they can get involved in the trial\, and the panelists will answer questions as time allows. \nRegister here:\nhttps://us02web.zoom.us/webinar/register/WN_URmi_dKHTQyNF6cjnOJa1A
URL:https://solvecfs.org/event/targeting-autophagy-a-clinical-trial-of-low-dose-rapamycin-for-me-cfs-long-covid-and-iaccis/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/06/UPDATEDSimmaronSolveWebinarSept4.png
END:VEVENT
END:VCALENDAR